MIRM stock news today

Citi kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $194 from $184.

Leerink Partners kept its Outperform rating on Mirum Pharmaceuticals (MIRM) with a price target of $140.

CORRECTION: RBC Capital kept its Outperform rating on Mirum Pharmaceuticals (MIRM).

RBC Capital kept its Outperform rating on Mirum Pharmaceuticals (MIRM).

Citizens JMP kept its Market Outperform rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $167 from $137.

HC Wainwright & Co. kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $202 from $200.

Cantor Fitzgerald kept its Overweight rating on Mirum Pharmaceuticals (MIRM) with a price target of $160.

TD Cowen kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $145 from $140.

Stifel kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $156 from $130.

Evercore ISI kept its Outperform rating on Mirum Pharmaceuticals (MIRM) with a price target of $146.

Morgan Stanley kept its Overweight rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $152 from $150.

Citi kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $184 from $160.

HC Wainwright & Co. kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $200 from $195.

RBC Capital kept its Outperform rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $155 from $135.

Citi kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $160 from $145.

Baird kept its Outperform rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $130 from $129.

HC Wainwright & Co. kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $195 from $140.

Citizens JMP kept its Market Outperform rating on Mirum Pharmaceuticals (MIRM).

What is the latest news on MIRM?

Nov 11, 2026: Citi kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $194 from $184. (Citi) · Nov 5, 2026: Leerink Partners kept its Outperform rating on Mirum Pharmaceuticals (MIRM) with a price target of $140. (Leerink Partners) · Nov 4, 2026: CORRECTION: RBC Capital kept its Outperform rating on Mirum Pharmaceuticals (MIRM). (CORRECTION: RBC Capital)

What are analysts saying about MIRM?

Nov 11, 2026: Citi kept its Buy rating on Mirum Pharmaceuticals (MIRM) and raised its price target to $194 from $184. · Nov 5, 2026: Leerink Partners kept its Outperform rating on Mirum Pharmaceuticals (MIRM) with a price target of $140. · Nov 4, 2026: CORRECTION: RBC Capital kept its Outperform rating on Mirum Pharmaceuticals (MIRM).